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A Permanent Solution for
a Temporary Problem
Transcatheter Valve-In-Valve Implantation for
Failed Transcatheter Aortic Valve Replacement*
Lutz Buellesfeld, MD,† Eberhard Grube, MD‡
Bern, Switzerland; and Bonn, Germany
Over the past decade, transcatheter aortic valve replacement
(TAVR) matured from an adventitious endeavor in the early
years to an established and paradigm-changing treatment
option for many patients with severe aortic valve stenosis.
However, lack of long-term data on device performance
as well as the obvious presence of procedure-specific com-
plications currently limit the expansion of this technology
toward lower-risk patients outside controlled and random-
ized clinical trials.
See page 571
Fortunately, we are continuously increasing our under-
standing of both mechanisms and the impact of procedure-
inherent risks, which enables us to take adequate measures
to overcome these issues. Reduction of device profile sizes,
improved screening standards, and better technical perfor-
mances led to a significant decrease of access site compli-
cations. Improved implantation techniques lowered the rate
of pacemaker implants, which is still higher for the
Medtronic CoreValve (Medtronic, Minneapolis, Minne-
sota) than for the Edwards Sapien prostheses (Edwards
Lifesciences, Irvine, California); but this complication does
not translate into prognostic relevance (1). Finally, rates of
embolic cerebral events are leveling down in more recent
publications, probably related to improved operator skills
and technical refinements. In addition, the advent of pro-
tection devices will further help to increase the safety of the
procedure.
Against this background, aortic regurgitation after
TAVR is one of the last remaining issues still underesti-
mated in terms of its incidence and clinical relevance,
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tants and proctors of Medtronic.mainly for 3 reasons: 1) aortic regurgitation after TAVR is
difficult to grade, given the lack of established evaluation
criteria in this new setting; 2) the prognostic impact of aortic
regurgitation in TAVR patients is largely unknown; and 3) we
have only anecdotal reports on bail-out strategies to deal with
aortic regurgitation after TAVR but no established concepts
with prospective assessment and validation.
In this issue of JACC: Cardiovascular Interventions, Tog-
gweiler et al. (2) present an interesting article reporting the
results of a multicenter study on frequency, feasibility, and
outcome of transcatheter valve-in-valve implantation with
the balloon-expandable Edwards prosthesis in patients with
significant aortic regurgitation after TAVR (so called
“transcatheter heart valve [THV]-in-THV”). Lack of pre-
specified criteria to perform this second implant and missing
information on regurgitation evaluation methods are signifi-
cant limitations of this study, but there are 2 main conclusions
that should be highlighted: 1) severe aortic regurgitation is rare;
and 2) interventional treatment of aortic regurgitation is
doable.
Severe Aortic Regurgitation Is Rare
Post-procedural presence of aortic regurgitation in patients
undergoing TAVR has been described since the introduc-
tion of this technique. In general, there are several mecha-
nisms that cause valvular or paravalvular leakages, which
must be understood and the actual one identified in order to
properly address this issue in a given case. Paravalvular regur-
gitation is always the result of incomplete annular sealing of the
device due to device misplacement, device–annulus mismatch,
incomplete device expansion, or unfavorable degeneration or
calcification patterns prohibiting full apposition (3) (Fig. 1).
alvular regurgitation is the result of restricted leaflet motion,
eaflet destruction, and under- or overexpansion of the device,
hich affects normal leaflet dynamics.
Good news is that, severe aortic regurgitation in patients
ndergoing TAVR is rare. In a total of 760 TAVR patients,
oggweiler et al. (2) observed an incidence of 3% for severe
ortic regurgitation, moderate aortic regurgitation in 10%,
nd less-than-moderate aortic regurgitation in 87% of cases.
hese numbers are well in line with previous publications,
eporting moderate-to-severe and severe aortic regurgitation
n 5% to 32% of TAVR patients (4–6). A total of 21
atients received a THV-in-THV to treat acute severe
egurgitation, which equals 2.8% of the study population.
dentified mechanisms were paravalvular in 18 cases, with
mplants too deep in 10 and too high in 8 cases, and valvular
n 3. Of note, severe paravalvular aortic regurgitation in
atients with optimal device implant depth was not ob-
erved in this study. However, the range of optimal implant
epths was not pre-defined, which might have biased the
nvestigators to classify implants as either too high or too
ow once severe aortic regurgitation was present, mistak-
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579enly neglecting alternative causes of paravalvular aortic
regurgitation.
Finally, the study points out that significant aortic regur-
gitation is poorly tolerated. This is a typical clinical finding,
because pressure-adapted ventricles can hardly cope with
rapid volume overload, particularly in the presence of addi-
tional underlying myocardial pathologies such as ischemic
heart disease. Consequently, severe aortic regurgitation was
associated with cardiogenic shock in 52% of patients, with
need for cardiopulmonary support and resuscitation in a
substantial number of cases. So there is no doubt that severe
aortic regurgitation is a relevant issue with significant clinical
impact. Interestingly, there is increasing evidence from other
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Figure 1. Selected Mechanisms of Paravalvular Regurgitation After Transc
Top row: ideal implant of CoreValve (Medtronic, Minneapolis, Minnesota) and
the match of landing zone and sealing part of the device; second row: implan
row: implant too deep, allowing for focal or circumferential regurgitation from
teristics preventing ideal device apposition.reports that, not only severe, but any kind of post-proceduralaortic regurgitation seems to be linked to a worsened outcome
(6,7). Therefore, we probably have to rethink our current
strategies on how we are dealing with nonsevere aortic regur-
gitation, potentially lowering the threshold to take corrective
measures to reduce or eliminate post-procedural leakage.
In summary, severe aortic regurgitation is rare but often
dramatic; and the prognostic impact of aortic regurgitation
is probably underestimated.
Interventional Treatment of Aortic Regurgitation
Is Doable
In theory, various options are available to handle aortic
Landing Zone 
Implant (sealing part) 
Implant (non-sealing part) 
r Aortic Valve Replacement
rds (Edwards Lifesciences, Irvine, California) prostheses. Last column indicates
high, allowing for focal or circumferential regurgitation from outside; third
e; bottom row: undersized prosthesis or presence of morphological charac-athete
Edwa
t too
insidregurgitation after TAVR, depending on the underlying
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 5 , 2 0 1 2
M A Y 2 0 1 2 : 5 7 8 – 8 1
Buellesfeld and Grube
Editorial Comment
580mechanism. Several techniques have been described in
anecdotal reports, including medical treatment only, post-
dilation, post-dilation with oversized balloons, pull-up ma-
neuvers for the self-expanding CoreValve prosthesis using a
snare, implantation of a second prosthesis (THV-in-THV),
implantation of focal occluders, or conversion to conven-
tional surgery (Fig. 2).
From the conceptual standpoint, THV-in-THV is useful
in cases of device misplacement too high or too low as well
as cases with valvular regurgitation. The reasonably high
success rate of 90% (19 of 21) reported by Toggweiler et al.
(2) with reduction of aortic regurgitation in all cases nicely
demonstrates the value of this approach. Short-term mor-
tality at 30 days tended to be increased compared with
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Figure 2. Bail-Out Options for Paravalvular Regurgitation
Top row: ideal match of landing zone and sealing part of the device; second
ing part toward the original landing zone (of note, avoid complete sinus isolat
implant at the same or slightly higher position extends the sealing part towar
case of undersizing or lack of complete apposition.patients without need for a second prosthesis (14.3% vs.
7.3%), but survival at 12 months was comparable (76% vs.
78%). The authors finally concluded that THV-in-THV for
treatment of significant aortic regurgitation is feasible and
results in satisfactory short- and mid-term outcome.
This corroborates the results of previously published
experiences using both the Edwards as well as the
Medtronic CoreValve prostheses. However, it does not
mean that THV-in-THV is generally the best and only way
to go. This approach is actually prone to fail in cases with
alternative causes such as device–annulus mismatch or
‘hostile’ calcification patterns. For instance, if the first
prosthesis is too small, the second will not correct for this.
One could select a larger size prosthesis to implant at a
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? 
if implant is too high, second implant at a deeper position extends the seal-
protect coronary artery perfusion); third row: if implant is too deep,
original landing zone; bottom row: various options must be considered inrow:
ion to
d the
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581deeper position in the outflow tract, but outflow tract
dimensions may exceed annulus dimensions, allowing again
for paravalvular gaps, and underexpansion of the valve in the
upper part will stress the leaflets, potentially affecting
long-term performance. In this scenario, other treatment
options must be considered.
It is quite remarkable that none of these alternative
regurgitation mechanisms—provided that they were not
overlooked—were observed in the present study, which
requires ideal screening, ideal device selection, and very
favorable native valve morphologies. Previously published
reports on aortic regurgitation after TAVR indicate that this
ideal environment does not usually exist. Therefore, it is still
the full bundle of treatment options outlined in the preced-
ing text that must be considered in these patients. In
summary, interventional treatment of aortic regurgitation is
doable, but mechanisms must be understood.
Future Perspective
Aortic regurgitation after TAVR is a procedure-related
issue that is certainly underestimated and currently not
always addressed in an adequate fashion. New standards for
valve assessment are needed to identify TAVR patients
requiring additional efforts to deal with this complication.
Because echocardiographic means are limited in describing
severity of paravalvular aortic regurgitation, particularly in
cases with circumferential or multiple jets, hemodynamic
assessment gains importance and seems to be predictive for
future events (8).
THV-in-THV is a suitable technique to deal with aortic
regurgitation after TAVR in selected cases if the underlying
mechanism allows for this approach, predominantly in device
misplacements and valvular regurgitation. However, we are
talking about a temporary problem as device misplacement is
shortly going to be eliminated by the introduction of reposi-
tionable prostheses, which enable intra-procedural positional
adjustments. In addition, future devices should and will pro-
vide dedicated paravalvular sealing mechanisms, which are
made to fill gaps between the device frame and the native valve. tFinally, three- and four-dimensional imaging tools will facili-
tate a precise assessment of the aortic valve anatomy, further
reducing the incidence of annulus-device mismatch.
Therefore, once dedicated devices and ideal screening
tools are established, there is not much room left for
regurgitation. In the meantime, papers like the present one
are certainly appreciated, because it is at least good to see
that we are able to deal with our own complication.
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